Loading…
Based on limited metadata, this FDA Warning Letter issued to SIA "Piejura" on July 3, 2018, addresses an unspecified product category classified as "Other," indicating it does not fall under standard FDA product classifications such as drugs, devices, or biologics. Without access to the full letter text or subject line details, the specific nature of the regulatory violations cannot be determined from the available information. The issuing office is also not identified in the metadata provided, limiting the ability to assess the regulatory scope or jurisdiction involved. Additional documentation would be necessary to understand the compliance issues cited in this warning.